{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:12:49Z","timestamp":1785334369836,"version":"3.55.0"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    Heart failure with preserved ejection fraction (HFpEF) remains a major cause of cardiovascular morbidity and mortality, yet lacks effective disease-modifying therapies owing to pronounced biological heterogeneity. Emerging evidence indicates that HFpEF is not merely a disorder of diastolic dysfunction but a systemic immunometabolic condition characterized by mitochondrial energetic impairment, altered substrate utilization, and chronic low-grade inflammation. This review examines the potential role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in modulating mitochondrial-inflammatory coupling in HFpEF and proposes this axis as an emerging mechanistic framework that may contribute to their therapeutic effects. We review preclinical and clinical evidence suggesting that HFpEF is associated with coordinated immunometabolic reprogramming across cardiomyocytes, endothelial cells, and cardiac immune populations, which may contribute to mitochondrial-inflammatory uncoupling. We discuss evidence that SGLT2 inhibitors act beyond glycosuria to potentially improve myocardial energetic efficiency, enhance mitochondrial quality control, reduce oxidative stress, and attenuate maladaptive inflammatory signaling, including inflammasome activation. Collectively, these findings suggest that restoration of mitochondrial-inflammatory coupling may partly explain the clinical benefits of SGLT2 inhibitors in HFpEF, although direct mechanistic evidence in humans remains limited. Finally, we highlight emerging biomarkers and future therapeutic strategies targeting the mitochondrial-inflammator\n                    <jats:italic>y<\/jats:italic>\n                    axis to support the development of precision medicine approaches for HFpEF.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2026.1881631","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:47:41Z","timestamp":1785332861000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mitochondrial-inflammatory coupling in HFpEF: an emerging mechanistic framework for understanding the cardioprotective effects of SGLT2 inhibitors"],"prefix":"10.3389","volume":"13","author":[{"given":"Muhammad Ghani","family":"Youniszad","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, The Affiliated Hospital of Shanxi Medical University, Shanxi Cardiovascular Hospital (Institute), Shanxi Clinical Medical Research Center for Cardiovascular Disease","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhi","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, The Affiliated Hospital of Shanxi Medical University, Shanxi Cardiovascular Hospital (Institute), Shanxi Clinical Medical Research Center for Cardiovascular Disease","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.mcna.2021.12.002","article-title":"Congestive heart failure","volume":"106","author":"Chen","year":"2022","journal-title":"Med Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction","volume":"42","author":"Jackson","year":"2021","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell","year":"2024","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41572-024-00540-y","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"Hamo","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction","volume":"17","author":"Borlaug","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"132304","DOI":"10.1016\/j.ijcard.2024.132304","article-title":"Heart failure with preserved ejection fraction epidemiology, pathophysiology, diagnosis and treatment strategies","volume":"412","author":"Abdin","year":"2024","journal-title":"Int J Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1161\/CIRCULATIONAHA.122.061846","article-title":"Myocardial metabolomics of human heart failure with preserved ejection fraction","volume":"147","author":"Hahn","year":"2023","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/cvr\/cvaa217","article-title":"Metabolic inflammation in heart failure with preserved ejection fraction","volume":"117","author":"Schiattarella","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.118.036259","article-title":"Mitochondrial dysfunction in heart failure with preserved ejection fraction","volume":"139","author":"Kumar","year":"2019","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jama.2020.26812","article-title":"Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"325","author":"Mueller","year":"2021","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1093\/cvr\/cvac166","article-title":"Cardiac metabolism in HFpEF: from fuel to signalling","volume":"118","author":"Capone","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12933-024-02366-0","article-title":"Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1-STING axis","volume":"23","author":"Shi","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1146\/annurev-pathmechdis-111523-023405","article-title":"Contributions of inflammation to cardiometabolic heart failure with preserved ejection fraction","volume":"20","author":"Thorp","year":"2025","journal-title":"Annu Rev Pathol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41569-025-01166-7","article-title":"Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets","volume":"22","author":"Mericskay","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jare.2022.03.003","article-title":"iNOS contributes to heart failure with preserved ejection fraction through mitochondrial dysfunction and Akt S-nitrosylation","volume":"43","author":"Guo","year":"2023","journal-title":"J Adv Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1161\/CIRCRESAHA.124.324706","article-title":"Glucagon receptor antagonist for heart failure with preserved ejection fraction","volume":"135","author":"Gao","year":"2024","journal-title":"Circ Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jare.2024.02.015","article-title":"Adiporon ameliorates the progression of heart failure with preserved ejection fraction via mitigating lipid accumulation and fibrosis","volume":"68","author":"Tan","year":"2025","journal-title":"J Adv Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1161\/CIRCULATIONAHA.122.062021","article-title":"Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial","volume":"147","author":"Hundertmark","year":"2023","journal-title":"Circulation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/CIRCRESAHA.120.317933","article-title":"Targeting mitochondria-inflammation circuit by \u03b2-hydroxybutyrate mitigates HFpEF","volume":"128","author":"Deng","year":"2021","journal-title":"Circ Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s44161-022-00032-w","article-title":"Immunometabolic mechanisms of heart failure with preserved ejection fraction","volume":"1","author":"Schiattarella","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1164\/rccm.202310-1848OC","article-title":"Characterization and mortality risk of impaired left ventricular filling in chronic obstructive pulmonary disease","volume":"211","author":"Abdo","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12933-025-02774-w","article-title":"Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment","volume":"24","author":"Gorica","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12933-025-02806-5","article-title":"Tirzepatide, a dual GIP\/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide","volume":"24","author":"Heged\u0171s","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"5386","DOI":"10.1038\/s41598-024-55996-5","article-title":"HFpEF as systemic disease, insight from a diagnostic prediction model reminiscent of systemic inflammation and organ interaction in HFpEF patients","volume":"14","author":"Zhou","year":"2024","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"117711","DOI":"10.1016\/j.biopha.2024.117711","article-title":"The NLRP3-inflammasome inhibitor MCC950 improves cardiac function in a HFpEF mouse model","volume":"181","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"B34","volume-title":"Left Ventricular Ejection Fraction","author":"Shams","year":"2025"},{"key":"B35","doi-asserted-by":"publisher","first-page":"100705","DOI":"10.1016\/j.xkme.2023.100705","article-title":"Heart failure with preserved ejection fraction with CKD: a narrative review of a multispecialty disorder","volume":"5","author":"Patel","year":"2023","journal-title":"Kidney Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail"},{"key":"B37","doi-asserted-by":"publisher","first-page":"13423","DOI":"10.1016\/j.jmoldis.2024.243","article-title":"Mechanistic relevance of ventricular arrhythmias in heart failure with preserved ejection fraction","volume":"25","author":"Bahrami","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12933-025-03023-w","article-title":"The SERCA-PLN-DWORF axis in cardiometabolic disease: mechanisms and therapeutic perspectives","volume":"25","author":"Kim","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jacc.2025.04.059","article-title":"Impact of body mass index, central adiposity, and weight loss on the benefits of tirzepatide in HFpEF: the SUMMIT trial","volume":"86","author":"Borlaug","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1001\/jamacardio.2024.4417","article-title":"Potassium nitrate in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"10","author":"Zamani","year":"2025","journal-title":"JAMA Cardiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1007\/s12265-025-10699-8","article-title":"Systemic interactions in HFpEF: a multiorgan perspective on pathways and therapeutic targets","volume":"18","author":"Cui","year":"2025","journal-title":"J Cardiovasc Transl Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"120495","DOI":"10.1016\/j.atherosclerosis.2025.120495","article-title":"Understanding MASLD\u2014from molecular pathogenesis to cardiovascular risk: a concise review for the clinical cardiologist","volume":"409","author":"Ratti","year":"2025","journal-title":"Atherosclerosis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"102660","DOI":"10.1016\/j.jchf.2025.102660","article-title":"Semaglutide and exercise function in obesity-related HFpEF: insights from the STEP-HFpEF program","volume":"13","author":"Borlaug","year":"2025","journal-title":"JACC Heart Fail"},{"key":"B44","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3724\/abbs.2024238","article-title":"Macrophage NLRP3-dependent IL-1\u03b2 production contributes to aortic fibrosis in heart failure with preserved ejection fraction","volume":"57","author":"Chen","year":"2024","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.jacc.2025.08.086","article-title":"Chronic kidney disease in patients with heart failure with a preserved ejection fraction: the underlying role of visceral adiposity","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12933-025-03030-x","article-title":"Succinate-GPR91 signaling promotes cardiomyocyte metabolic reprogramming and NAD(+) production to alleviate HFpEF","volume":"25","author":"Jia","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jchf.2024.02.018","article-title":"Targeted metabolomic profiling of dapagliflozin in heart failure with preserved ejection fraction: the PRESERVED-HF trial","volume":"12","author":"Selvaraj","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B48","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-med-042220-022745","article-title":"Heart failure with preserved ejection fraction: mechanisms and treatment strategies","volume":"73","author":"Omote","year":"2022","journal-title":"Annu Rev Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jacc.2021.07.042","article-title":"Coronary microvascular dysfunction across the spectrum of cardiovascular diseases: JACC state-of-the-art review","volume":"78","author":"Del Buono","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jare.2024.02.006","article-title":"Single-cell transcriptomic profiling of heart reveals ANGPTL4 linking fibroblasts and angiogenesis in heart failure with preserved ejection fraction","volume":"68","author":"Li","year":"2025","journal-title":"J Adv Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/heartjnl-2021-319605","article-title":"Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management","volume":"108","author":"Gevaert","year":"2022","journal-title":"Heart"},{"key":"B52","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jcmg.2018.12.034","article-title":"Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods","volume":"13","author":"Obokata","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/ejhf.2741","article-title":"Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives","volume":"24","author":"van Woerden","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s41467-025-56885-9","article-title":"FGF21 Protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","first-page":"103081","DOI":"10.1016\/j.redox.2024.103081","article-title":"FBXL4 Protects against HFpEF through Drp1-mediated regulation of mitochondrial dynamics and the downstream SERCA2a","volume":"70","author":"Abudureyimu","year":"2024","journal-title":"Redox Biol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jacc.2020.11.051","article-title":"HFpEF: should we consider diabetic patients separately?: the cardiomyocytes say yes","volume":"77","author":"Hulot","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1161\/CIRCRESAHA.123.324103","article-title":"Blunted cardiac mitophagy in response to metabolic stress contributes to HFpEF","volume":"135","author":"Yoshii","year":"2024","journal-title":"Circ Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"103424","DOI":"10.1016\/j.redox.2024.103424","article-title":"Schaftoside improves HFpEF through regulation the autophagy-lysosome pathway by allosterically targeting CaMKII-\u03b4","volume":"78","author":"Zhang","year":"2024","journal-title":"Redox Biol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41401-024-01265-0","article-title":"Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway","volume":"45","author":"Ni","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"B60","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fcvm.2019.00186","article-title":"SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function","volume":"6","author":"Maejima","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"103149","DOI":"10.1016\/j.cpcardiol.2025.103149","article-title":"SGLT2 inhibitors and cardiac fibrosis: a comprehensive review","volume":"50","author":"Karakasis","year":"2025","journal-title":"Curr Probl Cardiol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1016\/S2667-2681(20)30042-0","article-title":"Sodium-glucose cotransporter 2 inhibitors in aortic stenosis: toward a comprehensive cardiometabolic approach","volume":"26","author":"Karakasis","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1679085","DOI":"10.3389\/fphar.2025.1679085","article-title":"The crosstalk between mitochondrial dysfunction and fatty acid metabolism in heart failure: mechanisms and therapeutic strategies","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s40618-023-02162-9","article-title":"The anti-inflammatory and immunological properties of SGLT-2 inhibitors","volume":"46","author":"Bendotti","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"B65","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12916-021-02185-0","article-title":"Ketone bodies: from enemy to friend and guardian angel","volume":"19","author":"Kolb","year":"2021","journal-title":"BMC Med"},{"key":"B66","first-page":"1829","article-title":"The anti-inflammatory effect of novel antidiabetic agents","volume":"12","author":"Theofilis","year":"2022","journal-title":"Life (Basel)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"101549","DOI":"10.1016\/j.molmet.2022.101549","article-title":"Cardiovascular protection by SGLT2 inhibitors\u2014do anti-inflammatory mechanisms play a role?","volume":"64","author":"Elrakaybi","year":"2022","journal-title":"Mol Metab"},{"key":"B68","doi-asserted-by":"publisher","first-page":"149854","DOI":"10.1016\/j.brainres.2025.149854","article-title":"Detection of PPID-interacting proteins in migraine rats by IP-MS and validation by bioinformatics analysis and experiments","volume":"1865","author":"Wang","year":"2025","journal-title":"Brain Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1007\/s12094-022-02805-y","article-title":"The role of the inflammasome and its related pathways in ovarian cancer","volume":"24","author":"Liu","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"9687925","DOI":"10.1155\/2022\/9687925","article-title":"Relevance of NLRP3 inflammasome-related pathways in the pathology of diabetic wound healing and possible therapeutic targets","volume":"2022","author":"Ding","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"B71","doi-asserted-by":"publisher","first-page":"103169","DOI":"10.1016\/j.redox.2024.103169","article-title":"Modulation of NLRP3 inflammasome-related-inflammation via RIPK1\/RIPK3-DRP1 or HIF-1\u03b1 signaling by phenothiazine in hypothermic and normothermic neuroprotection after acute ischemic stroke","volume":"73","author":"Jiang","year":"2024","journal-title":"Redox Biol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","article-title":"An update on the regulatory mechanisms of NLRP3 inflammasome activation","volume":"18","author":"Paik","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"79","DOI":"10.15698\/cst2022.10.272","article-title":"Pyroptosis in NLRP3 inflammasome-related atherosclerosis","volume":"6","author":"Zeng","year":"2022","journal-title":"Cell Stress"},{"key":"B74","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12974-022-02626-4","article-title":"GSK872 And necrostatin-1 protect retinal ganglion cells against necroptosis through inhibition of RIP1\/RIP3\/MLKL pathway in glutamate-induced retinal excitotoxic model of glaucoma","volume":"19","author":"Liu","year":"2022","journal-title":"J Neuroinflammation"},{"key":"B75","doi-asserted-by":"publisher","first-page":"925435","DOI":"10.3389\/fcimb.2022.925435","article-title":"Outer membrane vesicles of Porphyromonas gingivalis trigger NLRP3 inflammasome and induce neuroinflammation, tau phosphorylation, and memory dysfunction in mice","volume":"12","author":"Gong","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41419-022-04786-w","article-title":"Targeted P2X7\/NLRP3 signaling pathway against inflammation, apoptosis, and pyroptosis of retinal endothelial cells in diabetic retinopathy","volume":"13","author":"Kong","year":"2022","journal-title":"Cell Death Dis"},{"key":"B77","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/ddr.21786","article-title":"Soluble epoxide hydrolase inhibitor trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea prevents hyperalgesia through regulating NLRC4 inflammasome-related pro-inflammatory and anti-inflammatory signaling pathways in the lipopolysaccharide-induced pain mouse model","volume":"82","author":"Cagli","year":"2021","journal-title":"Drug Dev Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s13287-022-03037-1","article-title":"Exosomal miR-17-5p from adipose-derived mesenchymal stem cells inhibits abdominal aortic aneurysm by suppressing TXNIP-NLRP3 inflammasome","volume":"13","author":"Hu","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B79","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ymthe.2024.11.018","article-title":"C-reactive protein promotes diabetic kidney disease via Smad3-mediated NLRP3 inflammasome activation","volume":"33","author":"Wang","year":"2025","journal-title":"Mol Ther"},{"key":"B80","doi-asserted-by":"publisher","first-page":"156154","DOI":"10.1016\/j.phymed.2024.156154","article-title":"Benzoylmesaconine mitigates NLRP3 inflammasome-related diseases by reducing intracellular K(+) efflux and disrupting NLRP3 inflammasome assembly","volume":"135","author":"Zhang","year":"2024","journal-title":"Phytomedicine"},{"key":"B81","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/jcdd9080256","article-title":"Biomarkers of HFpEF: natriuretic peptides, high-sensitivity troponins and beyond","volume":"9","author":"Morfino","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"B82","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jacc.2024.04.038","article-title":"Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF program","volume":"84","author":"Schou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.cjca.2024.04.006","article-title":"Heart failure with preserved ejection fraction in the elderly population: basic mechanisms and clinical considerations","volume":"40","author":"Gharagozloo","year":"2024","journal-title":"Can J Cardiol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"20072","DOI":"10.1038\/s41598-022-24226-1","article-title":"Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events","volume":"12","author":"Regan","year":"2022","journal-title":"Sci Rep"},{"key":"B86","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12933-025-02688-7","article-title":"Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction","volume":"24","author":"Menghoum","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jamacardio.2024.3810","article-title":"Cardiac myosin inhibition in heart failure with normal and supranormal ejection fraction: primary results of the EMBARK-HFpEF trial","volume":"10","author":"Shah","year":"2025","journal-title":"JAMA Cardiol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"105594","DOI":"10.1016\/j.jaccas.2025.105594","article-title":"HFpEF diagnosis: a controversial construct in modern cardiology","volume":"30","author":"Bellicini","year":"2025","journal-title":"Case Rep"},{"key":"B89","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1093\/eurheartj\/ehag175","article-title":"Heart failure and preserved ejection fraction: pathophysiology, clinical assessment, and management of exercise intolerance","volume":"47","author":"Landsteiner","year":"2026","journal-title":"Eur Heart J"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1881631\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:47:42Z","timestamp":1785332862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1881631\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":89,"alternative-id":["10.3389\/fcvm.2026.1881631"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1881631","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1881631"}}